ClinicalTrials.gg
Not yet recruitingNCT06446388Updated Jun 6, 2024

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

A Phase 2 interventional study of QLS31905 and Oxaliplatin in Advanced Solid Tumor, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-06.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
360
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participate in the study and sign the form;
  • (ECOG) performance status score of 0-1;
  • Expected survival time ≥ 3 months;
  • or cytologically confirmed locally advanced unresectable or solid tumors;
  • No prior systemic anti-tumor treatment for locally advanced unresectable or metastatic disease;
  • Tumor tissue samples determined to be positive for Claudin18.2 by immunohistochemistry (IHC);
  • At least one per v1.1;
  • Patients with adequate cardiac, liver, renal function, etc.

Exclusion criteria

Exclusion Criteria:

  • History of other than the target cancer within 5 years prior to the first dose of the product ;
  • Underwent major organ surgery (excluding needle ) or had significant trauma within 28 days prior to enrollment, or requires elective surgery during the study;
  • Known central nervous system ;
  • Patients with ; patients with ; patients who test positive for syphilis, or patients with a known history of or positive HIV screening test; Patients with a known history of psychoactive drug abuse, alcohol abuse, or substance abuse;
  • Patients with added risks associated with the study or may interfere with the interpretation of study results as determined by the investigator, or deemed unsuitable by the investigator and/or sponsor.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    QLS31905 + oxaliplatin + capecitabine

    Gastric/gastroesophageal junction cancer participants will be treated with QLS31905 at doses determined by the phase I study in combination with oxaliplatin and capecitabine.

    Drug: QLS31905 · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    QL1706 + oxaliplatin + capecitabine

    Gastric/gastroesophageal junction cancer participants will be treated with QL1706 in combination with oxaliplatin and capecitabine.

    Drug: Oxaliplatin · Drug: Capecitabine · Drug: QL1706

  • Experimental
    QLS31905 + oxaliplatin + capecitabine + QL1706

    Gastric/gastroesophageal junction cancer participants will be treated with QLS31905 at doses determined by the phase I study in combination with oxaliplatin and capecitabine+ QL1706.

    Drug: QLS31905 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: QL1706

  • Experimental
    QLS31905 + gemcitabine+cisplatin

    Biliary tract cancer will be treated with QLS31905 at doses determined by the phase I study in combination with gemcitabine and cisplatin.

    Drug: QLS31905 · Drug: Gemcitabine · Drug: Cisplatin

  • Experimental
    QL1706 + gemcitabine+cisplatin

    Biliary tract cancer will be treated with QL1706 in combination with gemcitabine and cisplatin.

    Drug: Gemcitabine · Drug: Cisplatin · Drug: QL1706

  • Experimental
    QLS31905 + gemcitabine+cisplatin+ QL1706

    Biliary tract cancer will be treated with QLS31905 at doses determined by the phase I study in combination with gemcitabine and cisplatin+ QL1706.

    Drug: QLS31905 · Drug: Gemcitabine · Drug: Cisplatin · Drug: QL1706

  • Experimental
    QLS31905 + standard chemotherapy

    Other solid tumor participants will be treated with QLS31905 at doses determined by the phase I study in combination with standard chemotherapy recommended by guidelines.

    Drug: QLS31905 · Drug: Chemotherapy drug

  • Experimental
    QL1706 + standard chemotherapy

    Other solid tumor participants will be treated with QL1706 in combination with standard chemotherapy recommended by guidelines.

    Drug: QL1706 · Drug: Chemotherapy drug

  • Experimental
    QLS31905 + standard chemotherapy + QL1706

    Other solid tumor participants will be treated with QLS31905 at doses determined by the phase I study in combination with standard chemotherapy and QL1706.

    Drug: QLS31905 · Drug: QL1706 · Drug: Chemotherapy drug

Interventions

  • Administered as an intravenous infusion.

  • 130 mg/m2, intravenous infusion, D1, up to 8 cycles.

  • 1000 mg/m2, oral, bid, D1-D14

  • 1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.

  • 25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.

  • DrugQL1706

    5 mg/kg, intravenous infusion,D1

  • DrugChemotherapy drug

    Standard chemotherapy recommended by guidelines.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the proportion of participants who have a best overall response of Complete Response (CR) or Partial Response (PR)

    Time frame: Approximately 24 months

Secondary outcomes

  1. Safety assessed by Adverse Events (AEs)

    An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom,or disease (new or exacerbated) temporally associated with the use of a medicinal product.

    Time frame: Approximately 24 months

  2. Safety assessed by incidence of serious adverse events (SAE)

    Adverse Event (AE) is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect,hospitalization, or medically important event.

    Time frame: Approximately 24 months

  3. Number of participants with laboratory value abnormalities

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Approximately 24 months

  4. Duration of Response (DOR)

    DOR is defined as the time from the date of the first response (CR/PR) until the date of radiological progressive disease or death due to any cause (whichever occurs first).

    Time frame: Approximately 24 months

  5. Progression Free Survival(PFS)

    PFS is defined as the duration from the subject's first dose of the investigational product to the first imaging confirmation of radiological progressive disease or death due to any cause (whichever occurs first).

    Time frame: Approximately 24 months

  6. Overall Survival (OS)

    OS is defined as the duration from the first dose of the investigational product to the time point when death occurs due to any cause.

    Time frame: Approximately 24 months

  7. Maximum concentration (Cmax)

    Cmax will be derived from the PK serum samples collected.

    Time frame: Approximately 24 months

  8. Time of the maximum concentration (Tmax)

    Tmax will be derived from the PK serum samples collected.

    Time frame: Approximately 24 months

  9. Terminal elimination half-life (T1/2)

    T1/2 will be derived from the PK serum samples collected.

    Time frame: Approximately 24 months

  10. Clearance (CL)

    CL will be derived from the PK serum samples collected.

    Time frame: Approximately 24 months

  11. Apparent volume of distribution during the terminal phase (Vz)

    Vz will be derived from the PK serum samples collected.

    Time frame: Approximately 24 months

  12. Number of anti-drug antibody (ADA) Positive Participants

    Immunogenicity will be measured by the number of participants that are ADA positive.

    Time frame: Approximately 24 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2024; primary completion for Jun 2026, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2024
First posted
Jun 6, 2024
StartEst.
Jun 30, 2024
Primary completionEst.
Jun 30, 2026
CompletionEst.
Dec 1, 2027
Last update
Jun 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06446388
Responsible party
Sponsor
First posted
Jun 6, 2024
Start date
Jun 30, 2024 (estimated)
Primary completion
Jun 30, 2026 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Jun 6, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 · Oxaliplatin · Capecitabine · Gemcitabine · Cisplatin · Iparomlimab/Tuvonralimab

Start the discussion